IPO - Profile

Summary

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. We are led by an experienced management team with a strong track record in the biotechnology and pharmaceutical industry. Our goal is to become a leading, patient-centric, fully integrated global rare disease company. Our current product pipeline is focused on rare gastrointestinal, or GI, disorders, and we intend to in-license or acquire additional transformational, differentiated rare disease assets. Our product More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$17.00 7,500,000 Positive High 46.75%

Offering Team

  • Legal counsel
  • Cooley LLP
  • Auditors
  • Ernst & Young AB

Deal Highlights

Deal Tracker

IPO Dates

Filing 08 Apr, 2021

Offer 09 Apr, 2021

Look Ahead

Lock Up Expiry Oct 09, 2021

IPO Terms

Offer Price $17.00
Offer Size 7M

Market Sentiments

Stock Price